Table S2.
Glycan | ΔXFPG9 (%) | ΔXFPG9Sulf (%) | ΔXFPG9SulfSia (%) | ΔXFRSH (%) | ΔXFRSHSulf (%) | ΔXFRSHSulfSia (%) | CHOPG9 (%) |
UGnF* | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 |
MGn* | 1.8 | 2.1 | 1.3 | 1.5 | 2.1 | 1.3 | 0.5 |
MGnF* | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.8 |
GnGn* | 45.0 | 50.9 | 17.5 | 41.1 | 56.1 | 18.1 | 3.0 |
GnGnX* | 1.3 | 1.9 | 0.5 | 0.8 | 1.0 | 0.2 | 0.0 |
GnGnF* | 0.8 | 1.4 | 0.1 | 0.5 | 0.5 | 0.2 | 69.8 |
MA* | 0.1 | 0.2 | 0.9 | 0.1 | 0.0 | 1.4 | 0.0 |
GnA* | 0.6 | 0.3 | 9.8 | 1.2 | 1.1 | 12.3 | 0.3 |
GnAF* | 0.1 | 0.1 | 0.2 | 0.2 | 0.0 | 0.5 | 17.7 |
AA* | 0.0 | 0.1 | 17.6 | 0.0 | 0.1 | 24.4 | 0.0 |
AAF* | 0.0 | 0.0 | 1.1 | 0.0 | 0.0 | 0.7 | 2.5 |
MNa* | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 1.9 | 0.0 |
GnNa* | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.3 | 0.0 |
ANa* | 0.0 | 0.0 | 2.9 | 0.0 | 0.0 | 6.4 | 0.0 |
ANaF* | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.7 | 0.3 |
NaNa* | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | 0.6 | 0.0 |
NaNaF* | 0.0 | 0.0 | 1.2 | 0.0 | 0.0 | 2.7 | 0.0 |
Man5† | 1.0 | 0.2 | 0.9 | 0.5 | 0.3 | 0.2 | 0.5 |
Man6† | 1.8 | 1.3 | 1.7 | 1.6 | 1.4 | 1.0 | 0.0 |
Man7† | 2.8 | 1.4 | 2.8 | 2.2 | 2.2 | 2.7 | 0.1 |
Man8† | 18.7 | 8.8 | 14.0 | 12.9 | 13.1 | 11.5 | 0.0 |
Man9† | 26.0 | 31.4 | 25.6 | 37.3 | 22.0 | 13.0 | 0.0 |
Gn‡ | 48.9 | 56.2 | 19.4 | 44.0 | 59.8 | 19.9 | 78.5 |
Gal‡ | 0.8 | 0.7 | 29.6 | 1.5 | 1.2 | 39.2 | 20.6 |
Sia‡ | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 12.5 | 0.3 |
Man5-9‡ | 50.3 | 43.1 | 44.9 | 54.5 | 39.0 | 28.4 | 0.6 |
Fuc§ | 0.9 | 1.5 | 3.2 | 0.7 | 0.5 | 4.8 | 95.6 |
N-glycan acronyms are based on the ProGlycAn nomenclature (www.proglycan.com).
Man5-9, oligomannosidic N-glycans with five to nine mannose residues.
Gn/Gal/Sia, sum of complex N-glycans with terminal GlcNAc/galactose/sialic acid residues; Man5-9, sum of oligomannosidic N-glycans with five to nine mannose residues.
Fuc, sum of core-fucosylated N-glycans.